RT Journal Article
SR Electronic
T1 Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.12.22273568
DO 10.1101/2022.04.12.22273568
A1 Campbell, Cori
A1 Wang, Tingyan
A1 Burrow, Rebekah
A1 Mandal, Sema
A1 Hippisley-Cox, Julia
A1 Barnes, Eleanor
A1 Matthews, Philippa C
YR 2022
UL http://medrxiv.org/content/early/2022/04/13/2022.04.12.22273568.abstract
AB Background HBV is the leading global cause of cirrhosis and primary liver cancer. The virus’s attributable disease burden in the UK is concentrated in vulnerable populatons including ethinic minorities, people experiencing homelessness and people born in high-prevalence countries. Despite this the UK HBV population has not been well characterised, and estimates of UK HBV prevalence and/or positivity rate vary widely across sources. We summarised datasets that are available to represent UK CHB epidemiology, consider differences between sources, and discuss deficiencies in current estimates.Methods We searched for estimates of CHB case numbers in the UK (incorporating incidence and/or prevalence-like data) across a range of available sources, including UK-wide reports from government bodies, publications from independent bodies (including medical charities and non-governmental organisations) and articles in peer-reviewed scientific journals. We present positivity rates from each respective data source but caution that estimates may not be representative of the true UK-wide population prevalence.Results and Discussion Six CHB case number estimates were identified, with three estimates reporting information concerning population subgroups, including number of infected individuals across age, sex and ethnicity categories., Estimates among sources reporting prevalence varied from 0.27% to 0.73%. An alterantive proxy for population prevalence (obtained via the UK antenatal screening programme which achieves over 95% coverage of every pregnant woman) estimated a CHB prevalence of <0.5%. Estimates varied by sources of error, bias and missingness, data linkage, and substantial “blind spots” in consistent testing and registration of HBV diagnoses. Multi-parameter evidence synthesis and back-calculation model methods similar to those used to generate estimates of HCV ad HIV population-wide prevalence may be applicable to HBV.Competing Interest StatementPCM is funded by Wellcome (grant ref 110110), by the Francis Crick Institute, and by University College London Hospitals NIHR BRC. CC's doctoral project is funded by the Nuffield Department of Medicine, University of Oxford and by GlaxoSmithKline. EB is funded by the Oxford NIHR Biomedical Research Centre and is an NIHR Senior Investigator. The views expressed in this article are those of the author and not necessarily those of the NHS, the NIHR, or the Department of Health. PCM, EB and CC are supported by the DeLIVER program "The Early Detection of Hepatocellular Liver Cancer" project is funded by Cancer Research UK (Early Detection Programme Award, grant reference: C30358/A29725). EB, TW, CC and PCM acknowledge support from the NIHR Health Informatics Collaborative.Funding StatementPCM is funded by Wellcome (grant ref 110110), by the Francis Crick Institute, and by University College London Hospitals NIHR BRC. CC's doctoral project is funded by the Nuffield Department of Medicine, University of Oxford and by GlaxoSmithKline. EB is funded by the Oxford NIHR Biomedical Research Centre and is an NIHR Senior Investigator. The views expressed in this article are those of the author and not necessarily those of the NHS, the NIHR, or the Department of Health. PCM, EB and CC are supported by the DeLIVER program "The Early Detection of Hepatocellular Liver Cancer" project is funded by Cancer Research UK (Early Detection Programme Award, grant reference: C30358/A29725). EB, TW, CC and PCM acknowledge support from the NIHR Health Informatics Collaborative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:QResearch ethics approval is with East Midlands-Derby Research Ethics Committee (reference 18/EM/0400).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOnly CC, TW, RB and JH-C have access to the QResearch individual-level patient data in order to ensure confidentiality of personal and health information, in accordance with the relevant licence agreements. QReseearch data access is according to the information on the QResearch website (www.qresearch.org).